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Abstract
Objective: To identify predictors of the progression from pre-dementia 
stages of cognitive impairment in Alzheimer’s disease is relevant to clinical 
management and to substantiate the decision of prescribing antidementia 
drugs. Method: Longitudinal study of a cohort of elderly adults with 
amnestic mild cognitive impairment and healthy controls, carried out 
to estimate the risk and characterize predictors of the progression to 
Alzheimer’s disease. Results: Patients with amnestic mild cognitive 
impairment had a higher risk to develop Alzheimer’s disease during follow-
up (odds ratio = 4.5, CI
95%
 [1.3-13.6], p = 0.010). At baseline, older age, 
lower scores on memory tests and presence of the APOE*4 allele predicted 
the progression from amnestic mild cognitive impairment to Alzheimer’s 
disease. In a sub sample of amnestic mild cognitive impairment patients, 
those who progressed to Alzheimer’s disease had lower cerebrospinal fluid 
concentrations of amyloid-beta peptide (Aβ
42
, p = 0.020) and higher 
concentrations of total TAU (p = 0.030) and phosphorylated TAU 
(p = 0.010), as compared to non-converters. Discussion: This is the first 
Brazilian study to report cerebrospinal fluid biomarkers in the prediction 
of the conversion from MCI to Alzheimer’s disease. Our data are in 
accordance with those reported in other settings. The measurement of 
cerebrospinal fluid total-TAU, phospho-TAU and Aβ
42
 may help identify 
patients with mild cognitive impairment at higher risk for developing 
Alzheimer’s disease. 
Descriptors: Alzheimer’s disease; Cognition disorders; Critical pathways; 
Biological indicators; Neurobehavioral manifestations
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Resumo
Objetivo: A identificação de preditores da conversão para a doença 
de Alzheimer em pacientes com comprometimento cognitivo leve é 
relevante para o manejo clínico e para decidir sobre a prescrição de drogas 
antidemência. Método: Estudo longitudinal em coorte de indivíduos idosos 
com comprometimento cognitivo leve amnéstico e controles saudáveis; 
estimativa do risco da progressão para doença de Alzheimer nos dois grupos; 
determinação das variáveis preditivas desse desfecho. Resultados: Pacientes 
com comprometimento cognitivo leve amnéstico apresentaram maior risco de 
desenvolver doença de Alzheimer ao longo do seguimento (odds ratio = 4,5, 
CI
95%
 [1,3-13,6], p = 0,012). Na avaliação inicial, idade mais avançada, 
escores mais baixos nos testes cognitivos e do alelo APOE*4 foram preditores 
da conversão do comprometimento cognitivo leve amnéstico para doença 
de Alzheimer. Em uma subamostra de pacientes com comprometimento 
cognitivo leve amnéstico, aqueles que progrediram para doença de Alzheimer 
tinham concentrações liquóricas mais baixas do peptídeo beta-amilóide 
(Aβ
42
, p = 0,020) e mais altas da proteína TAU total (p = 0,030) e TAU 
fosforilada (p = 0,010) do que os pacientes que não progrediram para doença 
de Alzheimer. Discussão: Este é o primeiro estudo brasileiro com biomarcadores 
liquóricos a relatar preditores da conversão comprometimento cognitivo leve-
doença de Alzheimer. Nossos dados biológicos (aumento de TAU total e fosfo-
TAU; redução de Aβ
42
), e podem auxiliar na identificação dos pacientes com 
comprometimento cognitivo leve com maior risco de evolução para demência. 
Descritores: Doença de Alzheimer; Transtornos cognitivos; Procedimentos 
clínicos; Indicadores biológicos; Manisfestações neurocomportamentais
Predictors of AD in patients with MCI
Revista Brasileira de Psiquiatria • vol 32 • nº 3 •set2010 • 217
Introduction
The term mild cognitive impairment (MCI) has been 
extensively used in clinical and research settings to describe 
subjects with objective cognitive impairment in one or more 
cognitive domains, with no evidence of clinically relevant 
functional impairment and dementia.1 Patients with MCI 
have an increased risk for developing dementia, particularly 
Alzheimer’s disease (AD), as compared to older adults without 
evidence of cognitive impairment, with annual progression rates 
ranging from 5 to 40% per year.2 Recent epidemiological studies 
have addressed the characteristics of pre-dementia states in 
Brazil. Hototian et al. reported a prevalence of 16% of cognitive 
impairment no dementia (CIND) in subjects over 60 years-old 
in Sao Paulo.3 Chaves et al. reported that the incidence of mild 
cognitive impairment, as defined by the Clinical Dementia 
Rating of 0.5, was 13.2 per 1000 elderly subjects per year.4 In 
a clinical setting, we have recently shown that patients with 
multiple-domain amnestic MCI tend to be older and to have 
a worse cognitive performance than those with single-domain 
MCI (amnestic and non-amnestic), suggesting that the former 
subgroup may represent a more severe stage of MCI.5,6 
The cross-sectional diagnosis of MCI still yields a heterogeneous 
group of patients, including subjects with varying degree of 
cognitive impairment.7 A significant proportion of subjects 
diagnosed as such may resume normal cognitive performance 
upon follow-up.8 Alternatively, other cognitive outcomes including 
non-AD dementia are also possible.9 
The characterization of clinical and biological predictors of 
conversion (MCI-AD) is clinically relevant, since it may help 
identify subjects at higher risk of AD, who are most likely to 
benefit from the early intervention with antidementia drugs.10 This 
perspective is even more relevant in the light of the development 
of drugs with disease-modifying properties.11 Most clinical and 
epidemiological studies have shown that advanced age, worse 
baseline cognitive performance and functional deficits are the 
important clinical predictors of progression to AD in MCI 
patients.12,13 Important biological predictors are the presence 
of the APOE*4 allele;14 low amyloid-β
42
 and elevated Tau and 
phospho-Tau protein in the CSF,15 whole-brain and hippocampal 
atrophy, the rate of brain atrophy in structural MRI16,17 and 
temporo-parietal hypometabolism/low blood flow in FDG-PET 
and SPECT.18,19 To the best of our knowledge, no study have so far 
addressed the contribution of clinical and biological predictors of 
the risk of progression from amnestic MCI to AD in the Brazilian 
elderly population. Therefore, the aim of the present study is to 
determine the annual rate of progression from amnestic MCI to 
AD in a clinical cohort of elderly subjects and the clinical and 
biological predictors of progression to AD.
Method
Detailed information on recruitment, clinical and 
neuropsychological evaluations, and diagnostic criteria can be 
found in a previous publication in this Journal, in which we 
addressed the cross-sectional characteristics of this cohort.6 Signed 
informed consents were obtained from all participants prior to 
enrolment. This study was approved by local Ethics Committee 
(process number 1053/02) and was performed according to the 
Helsinki Declaration.
1. Patients
Two hundred and fifty-eight outpatients (75% female) were 
assessed at the Institute of Psychiatry, University of Sao Paulo, 
Brazil, between December 2001 and March 2009 (mean age: 
70.6 ± 6.8 years; mean education: 9.8 ± 5.7 years). At baseline 
assessment, 73 subjects were diagnosed with AD, 97 had amnestic 
MCI (20 with single-domain amnestic MCI and 77 multiple-
domain amnestic MCI), and 88 were cognitively unimpaired 
(controls).  
2. Clinical and neuropsychological assessment
All subjects were examined by an expert multidisciplinary team, 
including geriatric psychiatrists, neurologists, geriatricians and 
neuropsychologists. Mental state examination was performed 
with the Brazilian version of the Cambridge Examination for 
Mental Disorders of the Elderly (CAMDEX) semi-structured 
interview,20,21 which yields scores for its cognitive subscale 
CAMCOG, the Mini-Mental State Examination (MMSE) and 
the Hachinski Ischemic Score. The Clock Drawing Test, which is 
part of the CAMCOG schedule, was additionally scored according 
to Sunderland’s guidelines. The 21-item Hamilton Depression 
Scale (HAM-D)22 was administered to rule out depressive 
symptomatology. Scores bellow 7 were considered as evidence of 
absence of current depressive episodes. Patients with evidence of 
depressive episodes were referred to psychiatric treatment and did 
not undergo cognitive neuropsychological assessments.   
Trained neuropsychologists administered neuropsychological 
examinations to all study participants. The neuropsychological 
battery included tests for episodic memory: the Rivermead 
Behavioural Memory Test (RBMT)23 and the Fuld Object-
Memory Evaluation (FOME),24 the Brazilian version of the Short 
Cognitive Test (SKT),25 verbal fluency (category: fruit); Trail 
Making Test A (TMT A), and Trail Making Test B (TMT B).  
Evidence of functional decline was based on the scores of the 
Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE)26 and on all available evidence of difficulties to 
perform basic and instrumental activities of daily living, reported 
by a close relative or caregiver, and on the patient’s self-report. 
Follow-up assessments were done in one-year intervals 
for all patients and controls in which the same clinical and 
neuropsychological protocols were administered.  
3. Diagnosis
Consensus diagnoses were reached in multidisciplinary expert 
meetings, taking into account clinical, neuropsychological, 
laboratorial, and neuroimaging data. AD was diagnosed according 
to the NINCDS-ADRDA criteria.27 The amnestic MCI diagnosis 
was made according to the following criteria: 1) subjective 
memory complain, preferably corroborated by an informant; 2) 
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objective memory impairment when performing cognitive tests 
of the assessment battery that was not severe enough to reach 
dementia diagnosis; 3) preserved global intellectual function; 
4) preserved or minimal impairments in activities of daily living; 
5) not demented.1,28 Evidence of objective memory impairment was 
defined as performance bellow 1.5 standard deviation in the memory 
tests (RBMT and/or FOME), adjusted for age and educational 
status.29 Subjects without evidence of cognitive impairment were 
included in the control group.  
4. APOE*4 genotyping
Genomic DNA was isolated from whole blood from each 
subject and the APOE genotyping was performed using the 
TaqMan® 5’-exonuclease allelic discrimination assay30 obtained 
from Applied Biosystems (Foster City, CA, USA) with primers 
and probes sets from inventoried assays. This methodology uses 
two PCR assays to screen for single nucleotide polymorphisms 
(rs429358, rs7412) within the exon 4 of APOE gene. Results 
from the individual assays were used to determine the ultimate 
APOE genotype.
5. Cerebrospinal fluid (CSF) collection
A sub sample of 45 aMCI patients consented to undergo 
lumbar puncture for CSF sampling and biomarker analysis. CSF 
samples were taken by lumbar puncture in the L3/L4 or L4/L5 
intervertebral space, with a 23-gauge needle and using 
polypropylene tubes, in the morning. A total of 12-15mL of CSF 
was collected and, then, centrifuged at 3200g for 10 minutes at 
4ºC. After centrifugation, the samples were separated in 0.5mL 
aliquots, and immediately frozen at -80º C until analysis without 
being thawed and re-frozen. 
6. CSF biomarkers analysis
The CSF biomarkers T-Tau, P-Tau
181
 and Aβ
1-42
 analyses 
were done in duplicate with the INNo-Bia AlzBio3 assay 
(Innogenetics, Ghent, Belgium), a multiplex microsphere-based 
Luminex xMAP platform that allows simultaneous analysis of 
these biomarkers. After pre-wetting of the filter plate with a wash 
buffer, a suspension of microsphere carrying the corresponding 
capturing antibodies (AT120, AT270 and 4D7A3 for t-Tau, 
P-Tau and Aβ
1-42
 respectively) was added to the plate. A mixture 
of biotinylated detection monoclonal antibodies, designed to 
detect specifically one of the capturing antibodies (HT7 for 
t-Tau and P-Tau and 3D6 for Aβ
1-42
), and 75μL of CSF or 
standards were added to the plate and incubated overnight in 
the dark. Next, the plate was washed and a detection conjugate 
(phycoerythrin-labeled streptavidin) was added and incubated 
for 1 h at room temperature. The plate was washed and after the 
addition of a reading solution (phosphate buffer saline) the assay 
was analyzed on a Luminex 100 IS platform (Luminex, Austin, 
Texas, US). Standard curves were constructed for each biomarker 
using a sigmoidal curve fitting method, and the mean fluorescence 
values for the duplicate CSF samples were used to determine the 
concentration of T-Tau, P-Tau and Aβ
1-42
.
7. Statistical analysis
We performed Pearson’s Chi-square test to assess differences in 
the distribution of gender and APOE*4 frequency among different 
diagnostic groups. Kolmogorov-Smirnov tests were done to assess 
the normality of the distribution for each continuous variable. As 
these analyses showed that all variables had normal or near-normal 
distribution, we carried out parametric statistical tests for all 
analyses. Univariate analysis of variance (ANOVA) was performed 
to assess mean differences for socio-demographic data, clinical 
variables, and scores on cognitive and neuropsychological tests 
among the diagnostic groups. If differences on socio-demographic 
or clinical variables known to influence cognitive performance 
were statistically significant among diagnostic groups in univariate 
analysis, we carried out multivariate analyses to control for the 
influence of these potential confounding variables on the scores 
of cognitive and neuropsychological tests. In addition, we carried 
out Bonferroni analyses for multiple comparisons to address mean 
differences in the scores of cognitive and neuropsychological tests 
between each diagnostic group. 
T-tests were done to ascertain mean differences in socio-
demographic, clinical scores on cognitive and neuropsychological 
tests and Pearson’s Chi-square analysis to assess for differences 
in the distribution of gender and APOE*4 frequency between 
converters and non-converters to AD in the control and MCI 
groups. Kaplan-Meyer survival analysis with log-rank tests were 
done to ascertain differences in the survival time prior to conversion 
in the MCI and control groups. Cox regression analysis, with 
backward likelihood ratio entry model, was performed to assess 
which variables were the most important predictors of conversion 
to AD. The probability for stepwise entry in the model was set 
at 0.05 and at 0.1 to be removed. The variables with significant 
statistical differences between converters and non-converters to 
AD in T-test or Pearson’s Chi-square analysis were the covariates in 
the Cox regression model. All statistical analyses were performed 
using SPSS v14.0 for Windows (SPSS Inc., Chicago, IL) and α 
was set at 5%. 
Results
Table 1 shows the socio-demographic data, APOE*4 frequency 
and the scores on the cognitive and neuropsychological assessments 
in the three groups in the baseline assessment. Patients with AD 
were older, less educated, had a higher frequency of APOE*4 and 
worse performance on cognitive and neuropsychological batteries 
as compared to aMCI and controls. One-hundred and eighty-three 
subjects had at least one follow-up assessment (40 AD patients, 
76 MCI and 71 controls). AD patients who did not comply 
with longitudinal reassessments had significant lower scores on 
the CAMOCG (p = 0.040) and verbal fluency animal category 
(p = 0.002). Patients with MCI (amnestic and non-amnestic) 
who did not complete at least one follow-up assessment were 
significantly older (p= 0.002), and had worse performance on 
the MMSE (p = 0.001), and on the CAMOCG (p = 0.001). 
No significant differences were observed in the control group 
according to compliance status. 
Predictors of AD in patients with MCI
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Sixteen subjects progressed to AD (3 in the control group 
and 13 in the MCI group) upon follow-up (mean follow-up of 
38.8 ± 17.7 months). Patients with the baseline diagnosis of 
amnestic MCI had a significantly increased risk for progression 
to AD (odds ratio = 4.5, 95% confidence interval of 1.3-13.6, 
p = 0.010). The annualized progression rate to AD was 6% in the MCI 
group, and 1% in the control group. Figure 1 shows the survival graph 
of MCI and controls. MCI subjects who progressed to AD were older, 
had higher frequency of APOE*4, and worse baseline scores on measures 
of memory and verbal fluency (Table 2). The variables age, gender, 
APOE*4, and  RBMT (screening and profile) scores, FOME (total and 
delay) scores, the verbal fluency fruit category and the SKT scores were 
covariates in the Cox regression analysis model. This analysis showed 
that older age [exp(β) = 1.11, S.E.(β) = 0.7, Wald = 4.2, p = 0.040], the 
presence of APOE*4 allele [exp(β) = 16.44, S.E.(β) = 1.01, Wald = 7.4, 
p = 0.006] and worse RBMT screening scores [exp(β) = 0.78, S.E.(β) = 0.1, 
Wald = 5.3, p = 0.020] were the best predictors of progression to AD 
in the patients with MCI.
In the sub sample of patients with aMCI who had CSF samples 
available for biomarker analysis (n = 45), 10 progressed to AD upon 
follow-up (MCI-AD) and 35 remained as MCI (non-converters, 
MCI-NC). These subjects had lower β-amyloid
42
 protein (MCI-AD, 
319.1pg/mL vs. MCI-NC, 443.5pg/mL, t = 2.32, p = 0.020), higher 
phospho-Tau protein (MCI-AD, 92.7pg/mL vs. MCI-NC, 56.8pg/
mL, t = -2.7, p = 0.010) and higher total Tau (MCI-AD, 141.0pg/
mL vs. MCI-NC, 92.3pg/mL, t = -2.25, t = 0.030).
Discussion
This is the first study to ascertain, in a clinical Brazilian 
elderly cohort, the risk of conversion from MCI to AD and its 
underlying cognitive and biological predictors. We show that 
the cross-sectional diagnosis of amnestic MCI confers a higher 
risk of progression to AD as compared to the ascertainment of 
unimpaired cognition. Older age, worse baseline memory function 
and the presence of the APOE*4 allele are the best predictors of 
progression to AD in patients with amnestic MCI. We further 
show that patients with MCI who convert to AD (MCI-AD), as 
compared to non-converters (MCI-NC), have a CSF biomarker 
signature that resembles the one found in AD patients (i.e. low 
β-amyloid
42
, high total Tau and high phospho-Tau). The present 
findings are in agreement with those from previous studies carried 
out in other countries and settings.31 Although it was based on a 
clinical cohort, we believe that the present evidence will add to the 
existing knowledge on the risk of AD in the Brazil, which has been 
accumulated mostly from epidemiological studies in this country. 
The annualized rate of progression to AD in our study (6%) 
was lower than the original estimate by Petersen et al.28 (10 to 
15% per year), but it is in agreement with more recent studies 
suggesting that the former rates may have been overestimated, 
given the smaller numbers provided by recent longitudinal 
observations.32 Attrition resulted in the unavailability to reassess 
21 patients with amnestic MCI. Because these subjects were 
older and had worse baseline cognitive performance, making 
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our estimate conservative, the annualized progression rate 
to AD of 6% may have been underestimated in this sample. 
Anyhow, our data are in agreement with a recent meta-
analysis on the risk of progression from MCI to AD.33 The 
discrepancy between different studies may be due to several 
reasons, namely: distinct diagnostic criteria for MCI and/or 
comprehensiveness of assessment schedules across different 
studies; lack of gold standards for cognitive evaluation;7,34 non-
objective definition of functional impairment and subsequent 
inaccuracy of the dementia threshold;35 recruitment of subjects 
with MCI at different stages of cognitive impairment;32,36 
and finally the diagnostic instability of the MCI concept, 
yielding longitudinal outcomes that are not necessarily related 
with baseline diagnoses.8,36 
In view of these limitations, biomarker technologies have been 
developed in the past years in an attempt to improve the specificity 
of the clinical diagnosis of MCI. The rationale is to depict the 
subjects at higher risk of evolving to AD from larger samples.37 
In the present study, we found that MCI subjects displaying an 
abnormal AD-like pattern of CSF biomarkers (i.e., lower Aβ
42
 
and higher total- and phospho-TAU) had an increased risk 
of progressing to dementia. Other techniques with promising 
diagnostic support are longitudinal measurements of whole-
brain and/or hippocampal atrophy with structural MRI, cerebral 
blood flow with SPECT, and cerebral metabolism or amyloid 
imaging with PET scans.16,18,38 Additionally, the combination of 
these diagnostic strategies seems to increase the predictive power 
to identify AD patients at the prodromal stages of the disease.39 
According to a recent task-force that proposed the revised 
Predictors of AD in patients with MCI
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